On January 28, the State Administration for Market Regulation (SAMR) announced on its official website that it has officially approved the market supervision bureaus of Shanghai, Jiangsu, Zhejiang, and Anhui to conduct a pilot program for cross-regional review of medical device advertisements within the Yangtze River Delta region. This initiative aims to further advance the development of a unified national market and promote integrated market supervision in the area.

The pilot program focuses on resolving bottlenecks in the medical device advertisement review process. By innovating the approval model, eligible applications will be processed under a "one-time application, single-location review, and one-number issuance" system across the region. Starting with a targeted approach, these practical measures are designed to significantly reduce the administrative burden and costs for advertisers, continuously optimize the business environment, and enhance service efficiency for enterprises. The program seeks to accumulate replicable and scalable experience for reforming and improving the advertisement review management system.